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Abstract: The SLC12 family of cation-chloride-cotransporters (CCCs) is comprised of potassium 
chloride cotransporters (KCCs), which mediate Cl− extrusion and sodium-potassium chloride 
cotransporters (N[K]CCs), which mediate Cl− loading. The CCCs play vital roles in cell volume 
regulation and ion homeostasis. The functions of CCCs influence a variety of physiological 
processes, many of which overlap with the pathophysiology of cardiovascular disease. Although 
not all of the cotransporters have been linked to Mendelian genetic disorders, recent studies have 
provided new insights into their functional role in vascular and renal cells in addition to their 
contribution to cardiovascular diseases. Particularly, an imbalance in potassium levels promotes the 
pathogenesis of atherosclerosis and disturbances in sodium homeostasis are one of the causes of 
hypertension. Recent findings suggest hypothalamic signaling as a key signaling pathway in the 
pathophysiology of hypertension. In this review, we summarize and discuss the role of CCCs in 
cardiovascular disease with particular emphasis on knowledge gained in recent years on NKCCs 
and KCCs.  
Keywords: cardiovascular disease; hypertension; atherosclerosis; electroneutral transport; cation-
chloride-cotransporters; KCCs; NKCCs 
 
1. Cardiovascular Disease 
Cardiovascular diseases (CVDs) are the leading cause of mortality globally. It has been estimated 
that countries in the European region alone spent GBP 80 billion on health care costs related to CVDs 
[1–3]. CVDs are a group of health complications that affect the heart and circulation, including 
coronary heart disease, heart attack, stroke, heart failure, arrhythmia, and more. Coronary heart 
disease (CHD) is mainly caused by reduced or blockage of blood flow to the heart and can lead to 
heart attacks (blocked blood flow to the heart) and heart failure (failure of the heart to pump blood). 
CHD could also cause heart valve problems and abnormal rhythms (arrhythmias). A stroke occurs 
due to blockages of blood flow to the brain. Risk factors associated with CVDs include hypertension, 
diabetes, atherosclerosis, smoking, obesity and high cholesterol. Among the risk factors, 
hypertension and atherosclerosis are the main underlying causes of CVD. The renal system plays a 
critical role in blood pressure homeostasis. Water retention in the kidney, due to increased sodium 
reabsorption, causes extracellular fluid (ECF) volume expansion [4]. The volume expansion 
contributes to the elevation of preload which contributes to the increase in blood pressure. 
Hypertension could also lead to atherosclerosis. Atherosclerosis is the process of hardening and 
narrowing of the blood vessels. Vascular proliferation is one of the contributing factors to the 
pathophysiology of atherosclerosis. Vascular proliferation is the phenotypic changes of the vascular 
smooth muscle cells (VSMCs), the most numerous cell type in the blood vessel, characterized by the 
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reversible transition from a quiescent contractile state to a synthetic migratory phenotype [5]. 
Although there are preventive measures to reduce the burden of CVDs, atherosclerosis is common 
in people over the age of 65 and 1.3 billion people worldwide are estimated to be hypertensive [1–3]. 
Thus current research aims are to discover novel targets for the treatment of CVDs. Our recent 
research developed a molecular compound termed ZT-1a for the treatment of stroke, by modulating 
the activities of cation chloride cotransporters (CCC) [6]. In the review, the focus is to summarise 
previous work and recent advances that attest to CCC’s growing potential as a therapeutic target for 
CVDs. 
2. Evolution of the Cation Chloride Cotransporter Family 
Comprehensive phylogenetic analysis by Hartmann et al. revealed the existence of a single 
ancestral cation chloride cotransporter (CCC) gene in the Archean, Methanosarcina acetivorans [7]. The 
ancestral gene appears to be the base of numerous duplication events which led to paralogous CCC 
subfamilies in Archean and eukaryotes. These subfamilies consist of sodium chloride cotransporter 
(NCC), sodium potassium chloride cotransporters (NKCCs, NKCC1 and NKCC2; with NCC 
collectively referred to as N[K]CCs), potassium chloride cotransporters (KCCs, KCC1–4), polyamine 
transporter (CCC9) and CCC-interacting protein (CIP1). NCC and NKCCs use Na+ in their 
stoichiometric translocation of Cl−, whereas KCCs using K+. CIP1 have been shown to  inhibit NKCC1 
activity [8] and enhance KCC2 [9] activity in cultured cells. CCC9 remains unclassified. CCCs provide 
electroneutral transport of sodium, potassium and chloride across the plasma membrane; with an 
exception of NCC, all CCCs are inhibited by several structurally similar compounds, such as 
bumetanide and furosemide (Table 1). It is important to note that KCCs are only weakly inhibited by 
these compounds. Further gene-loss events resulted in the complex distribution of CCCs across the 
taxa. 
Gene duplication within the CCC subfamilies of vertebrates resulted in subfunctionalization [7]. 
This process created a number of isoforms with different expression patterns and functionality in 
various organs and tissues. Further variants are generated by alternative splicing of the isoforms with 
various ratios of expression in human tissues (Table 1). 
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Table 1. Major characteristics of Cl−-coupled cation cotransporters [10–13]. 
Gene 
Human 
chromosome 
localization 
Protein 
Transported 
ions 
Alternative 
spicing 
Tissue distribution, 
cellular/subcellular expression 
Link to disease Inhibitors, IC50 (μM) 
SLC12A2 5q23.3 NKCC1 Na+, K+, Cl− 
Isoforms A 
and B [14] 
Ubiquitous: basolateral 
membrane of epithelial cells, 
non-epithelial cells 
Schizophrenia [15] 
Bumetanide, 0.05–0.60; 
Furosemide, 10–50; 
ARN23746 [16]  
Azosemide, 0.246–
0.197 
SLC12A1 15q21.1 NKCC2 Na+, K+, Cl− 
Isoforms A, B 
and F [17] 
Kidney-specific: apical 
membrane of the thick 
ascending limb 
Bartter syndrome type I [18] 
Bumetanide, 0.10–0.50; 
Furosemide, 15–60 
SLC12A3 16q13 NCC Na+, Cl− NA 
Kidney-specific: apical 
membrane of the distal 
convoluted tubule 
Gitelman syndrome [19] 
Hydrochlorothiazide, 
70 [20]; 
Metolazone, 0.3 [21]  
SLC12A4 16q22 KCC1 K+, Cl− NA Ubiquitous NA 
Bumetanide, 60 [22]; 
Furosemide, 40 [22]; 
DIOA, ~10 
SLC12A5 20q13 KCC2 K+, Cl− NA Neurones Epilepsy [23] 
Bumetanide, 55; 
Furosemide, 10; 
VU 0463271, 0.061 [24]; 
DIOA, ~10 
SLC12A6 15q14 KCC3 K+, Cl− 
Isoforms A 
and B [25] 
Ubiquitous 
Agenesis of the Corpus 
Callosum with Peripheral 
Neuropathy (ACCPN) [26] 
Bumetanide, 40; 
Furosemide, 25; 
DIOA,~10 
SLC12A7 5p15 KCC4 K+, Cl− NA Ubiquitous Renal tubular acidosis [27] 
Bumetanide, 900; 
Furosemide, 900; 
DIOA, ~10 
SLC12A8 3q21 CCC9 NA 
Six isoforms 
[28] 
Ubiquitous Psoriasis [28] NA 
SLC12A9 7q22 CIP1 NA NA Ubiquitous NA NA 
NA, information not available. 
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The topology of all CCCs consists of 12 transmembrane domains (TM) domains and large 
intracellular amino (N) and carboxyl (C) terminal domains [29]. Notably, the KCC and N[K]CC 
subfamilies vary in their position of the long extracellular loop: between TM5 and TM6 in KCCs and 
between TM7 and TM8 in the N[K]CC subfamily. Within the isoforms of the subfamilies, the TMs 
and C-terminus are highly conserved. In contrast, the N terminus is considerably more variable 
amongst isoforms [29]. Binding of diuretics occurs in the conserved TMs and not the variable termini 
[29]. Therefore, loop diuretics like furosemide and bumetanide are used to characterize the 
physiological function of KCCs and NKCCs with little specification for each paralog. The termini are 
involved in the regulation of transport activity indicative of the sites for post-translational 
modifications like phosphorylation that are located within them. 
Although the family N[K]CC and KCC reciprocally regulate Cl− uptake for N[K]CCs and 
extrusion for KCCs, the mechanism of coupled ion translocation is considered to be similar. In an 
alternating access model for NKCCs proposed by Haas, the carriers only move when they are either 
fully loaded or completely empty [30]. Following ions binding in a strictly ordered sequence, a 
conformation change occurs that causes the transporter to face the opposite direction and adopt a 
new form (inwards facing state during extracellular ion binding and vice versa) [30]. The ions are 
subsequently released in the same order they were bound. Once empty, the transporters return to the 
original form ready for a new cycle. Recent 3D models have been made that support Haas, however, 
due to the many differences between paralogs of CCC family members, inferring functional 
properties from data obtained for a different family member may not be desirable [29]. 
3. Functional Regulation of the Cation Chloride Cotransporter Family 
It is generally accepted that regulation of CCC function is accomplished through 
phosphorylation/dephosphorylation events. Phosphorylation/dephosphorylation reciprocally 
regulate the N[K]CC and KCC via a network of serine-threonine kinases and phosphatases [31–33]. 
Phosphorylation activates the Na+ dependent subfamily and inactivates the K+ dependent subfamily 
and vice versa [34]. The master regulator of CCCs, With-No-K (Lysine) kinases (WNKs) regulate the 
CCCs via their downstream targets, Ste20/SPS1-related proline/alanine-rich kinase (SPAK) or the 
SPAK homolog oxidative stress-responsive kinase 1 (OSR1) [31–33]. Threonine and serine residues 
of the CCCs are phosphorylated as a result of this downstream activation. The number and position 
of phospho-sites vary between different family members as they are not evolutionarily conserved 
among isoforms and paralogs [29]. Phosphatases such as protein phosphatase 1 (PP1) counterbalance 
the action of the kinases [35]. 
Recent data by Lee et al. [36] challenge the current understanding of KCC regulation. Lee and 
team reported that phosphorylation of KCC2 specific residue, Ser940, by protein kinase C (PKC) has 
been shown to activate KCC2, an isoform exclusively expressed in the nervous system. However, the 
phosphorylation of highly conserved threonine residues in all KCCs is ubiquitously associated with 
inactivation [33,37–39]. Thus, the phosphorylation-mediated-activation of KCC2 may be an adaptive 
mechanism to assist with KCC2 functions in the nervous system [38,40,41]. Gene mutations in WNK1 
and WNK4 result in over-activation of the WNK-SPAK/OSR1 pathway, therefore increased 
phosphorylation and activation of NCC occurs in the kidney, resulting in hypertension [42,43]. 
Recent studies highlight multiple other signaling factors and regulators of CCC activities that are 
implicated in cardiovascular disease [44–48]. More specifically, the functional regulation of CCCs in 
vascular smooth muscle cells and renal cells play a significant role in the pathogenesis of 
atherosclerosis and Mendelian and non-Mendelian forms of hypertension [45,49–51]. 
4. Role of NCC in Cardiovascular Disease 
Previous studies have demonstrated that the thiazide-sensitive NCC in the distal convoluted 
tubule (DCT) plays an important role in blood pressure regulation and that loss of NCC function 
causes hypotension (Figure 1). Contrastingly, gain-of-function mutations that result in the 
overactivation of NCC cause Familial Hyperkalemic Hypertension (FHHt) or Gordon’s syndrome, a 
Mendelian form of hypertension. FHHt is caused by genetic mutations in genes encoding for the 
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regulatory WNK-SPAK/OSR1 and its upstream regulator, an E3 ubiquitin ligase complex containing 
kelch-like 3 (KLHL3) and Cullin 3 (CUL3). Indeed, current research is focused on identifying novel 
targets within the WNK-SPAK/OSR1 pathway for use in FHHt and potentially non-Mendelian forms 
of hypertension. A large body of evidence has demonstrated that inhibition of various components 
of the WNK-SPAK/OSR1-NCC pathway is an effective drug target for reducing blood pressure [52]. 
However, the lack of specificity across WNK and SPAK isoforms is challenging for the drug discovery 
process [45]. A more detailed account of the CUL3/KLHL3-WNK-SPAK/OSR1 pathway as a target 
for hypertension can be found in the review by Ferdaus et al. [45]. 
 
Figure 1. Expression of cation-chloride-cotransporters in the kidney. Alpha-intercalated cells in the 
collecting duct (CD) secretes acid via the apical H-ATPase and H+/K+ exchanger and reabsorbs 
bicarbonate via the basolateral Cl/HCO3 exchanger. Efflux of Cl− through the potassium chloride co-
transporter-4 (KCC4) is important to maintain the electrochemical gradient to facilitate the acid 
secretion activities of the alpha-intercalated cells. Loss of KCC4 leads to renal tubular acidosis, which, 
if left untreated, could lead to cardiac arrhythmias. Sodium-chloride-cotransporters (NCCs) are 
exclusively expressed in the distal convoluted tubule (DCT). Gain-of-function mutations in regulatory 
genes that lead to the over activation of NCC cause Familial Hyperkalemic Hypertension (FHHt). 
Sodium potassium chloride cotransporters-2 (NKCC2) is expressed in the thick ascending limb (TAL). 
Loss-of-function mutations of NKCC2 results in the salt-wasting phenotype of type 1 Bartter 
Syndrome. 
5. Role of KCCs in Cardiovascular Disease 
Loop diuretics, such as furosemide and bumetanide, are antihypertensive which acts primarily 
on NKCC2 in the thick ascending limb of the Loop of Henle (TAL) to inhibit NaCl reabsorption and 
consequently reduce blood pressure [53]. However, loop diuretics have also been shown to act on 
KCCs [48,54,55]. Although much research has centered on understanding the role of KCC in vascular 
cells, a growing body of evidence indicates KCC participation in renal physiology [56,57]. Two 
isoforms, KCC3 and KCC4 are differentially expressed in the kidney reflecting the variability of their 
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role in cardiovascular disease; KCC3 may regulate glucose reabsorption while KCC4 participates in 
maintaining renal salt and acid-base balance [56,57]. A secondary effect of loop diuretics is 
vasodilation. Several members of the KCCs (KCC1-3-4) family have been identified in the VSMCs 
[48,54,55]. This evidence suggests a role for KCC in the VSMCs. Researchers have reported that 
growth factors such as platelet-derived growth factors (PDGF) [48] that promote and inhibitors such 
as nitric oxide (NO) [58] that inhibit phenotypic changes of the VSMCs are also modulators of KCCs 
in the VSMCs. Together with the observation of cardiovascular defects such as arterial hypertension 
and impairment in cell volume signalling in renal tubules, in three models of KCC3 null mice [59,60], 
the evidence makes a compelling case for a pathogenic role of KCC beyond its well-studied 
physiological role in the erythrocytes. Here, we will discuss the substantial body of evidence 
suggesting a role of KCCs and their signaling pathways in the pathogenesis of cardiovascular disease. 
5.1. KCC in Vascular Cells 
Contractile VSMCs undergo phenotypic changes to proliferative/migratory cells in response to 
serum factors such as PDGF. Proliferative VSMCs in turn, forms lesions that are evident in vascular 
diseases such as atherosclerosis. Due to KCC participation in other proliferative diseases such as 
cancer [61] and reports of the functional significance of cell volume regulation in cell proliferation 
[62], a role for KCC in cell proliferation and migration is plausible. Indeed, Zhang and colleagues 
observed inhibition of KCC basal activity following a 24 h serum deprivation and recovery upon 
serum addition [48]. Using synthetic VSMCs as a model system, an increase in KCC1 and KCC3 
activity after short term exposure (10 min) to PDGF and increase in KCC1 but decrease in KCC3 
mRNA expression after long term exposure (12 h) was observed [48]. Consistent with evidence that 
KCC1 and KCC3 mRNA expression follows a 2:1 ratio in VSMCs [63], the results suggest that KCC1 
may play a more vital role in PDGF-mediated modulation of VSMCs. 
AG-1296, an inhibitor of the PDGF receptor, abolished the PDGF-induced increase in KCC 
activity, indicating PDGF activation of KCC through its membrane receptors [48]. Dimerization and 
autophosphorylation of PDGF membrane receptors initiate downstream signal transduction through 
molecules such as phosphatidyl-inositide-3-kinases (PI3-K) and mitogen-activated protein kinase 
(MAPK). Pharmacological inhibition demonstrated that PDGF-mediated activation of KCC occurs 
via the P13K/Akt pathway [64]. Although the inhibition of MAPK by PD98059 has been shown to 
suppress KCC activity in red blood cells [65] and breast cancer cells [66], no evidence of MAPK 
involvement in PDGF activation by KCC was found. Notably, the study on breast cancer cells found 
that stimulation of KCC4 mRNA levels by insulin-like growth factor-1 (IGF-1), another serum growth 
factor, was inhibited by 65% with an inhibitor of ERK1/2, PD98059, but was insensitive to the p38 
MAPK inhibitor, SB202190 [66]. While inhibitor of Akt, LY 294002, only inhibited IGF-1 stimulation 
of KCC4 mRNA levels by 35% [66], suggesting a larger role for ERK1/2 in the regulation of KCC 
expression. However, it is important to note that the length of incubation varied between the 
experiments: 1 h for VSMCs and 3 h for red blood cells and breast cancer cells. Therefore, the 
importance of each signaling pathways could vary between cell types. The researchers also found 
that calyculin A, an inhibitor of protein phosphatase 1 (PP1), significantly inhibited PDGF regulation 
of KCC by 60% [64], suggesting the participation of PP1 in KCC modulation by the PDGF-PI3K 
pathway (Figure 2). As there is no clear evidence of PI3K regulation of PP1, further research will need 
to determine whether additional components of downstream of PI3K exists is crucial. 
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Figure 2. KCC is implicated in atherosclerosis and is a potential therapeutic target for hypertension. 
Potassium chloride channel (KCC) in vascular cells is regulated via the platelet-derived growth factor 
(PDGF) and nitric oxide (NO), both of which are implicated in atherosclerosis and vasodilation 
respectively. PDGF regulates KCC through the dimerization of PDGF receptors (PDGFR) and the 
subsequent activation of phosphoinositide 3-kinase (PI3K). Through an unknown mechanism, PI3K 
activates protein phosphatase 1 (PP1) which dephosphorylates and actives KCC. Activation of KCC 
could enhance the phenotypic switching of vascular smooth muscle cells (VSMCs) into a diseased 
state. NO regulates KCC via the nitric oxide/cyclic guanosine monophosphate/protein kinase G 
(NO/cGMP/PKG) pathway. PKG activates PP1 through an unknown mechanism leading to KCC 
activation and consequent vasodilation. KCC could be a potential therapeutic target for hypertension. 
Apelin is cardioprotective and a common modulator of both pathways. 
Although the evidence is clear that PDGF regulates KCC, it is not clear how KCC activation 
plays a role in PDGF-mediated signaling to promote atherosclerosis. Recent kinetic studies of KCC 
activity found evidence to support direct KCC involvement in vascular phenotypic changes [50]. The 
researchers found significant changes in the kinetic parameters for the co-transport of Cl− between 
early, intermediate and late VSMC synthetic phenotypes. Increased KCC1 and KCC4 expression in 
the late synthetic VSMC in comparison to earlier states suggest a functional role of KCC in 
phenotyping switching to a diseased state. 
Nitric oxide acts to regulate the function of VSMCs via cGMP-dependent activation of protein 
kinase G (PKG) to promote VSMC relaxation. Activators of the NO/cGMP/PKG pathway such as 
sodium nitroprusside, NONOates (NO donors) and 8Br-cGMP (PKG substrate) have been shown to 
stimulate KCC activity, mRNA and protein expression. Inhibitors such as KT5823 (PKG inhibitor), 
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calyculin A and genistein (PP1 inhibitor) inhibit KCC activity, mRNA and protein expression [67]. 
Researchers also found that when the vasodilators hydralazine and sodium nitroprusside were 
added to pre-contracted arteries, the arteries relax despite the blocking of all pathways except for 
KCC [67]. Interestingly, the NO signaling preferentially increased KCC3b mRNA 8.1-fold in 
comparison to 2.5-fold for KCC3a isoform despite a 3:1 KCC3a:KCC3b mRNA expression [68]. 
Overall, this indicates KCC contribution to the vascular effects of these vasodilators. Studies by Di 
Fulvio and team reported NO/cGMP/PKG signaling pathway and PKG participation in the regulation 
of KCC1 [58] and KCC3 [63] mRNA expression respectively. Further studies by Adragna et al. found 
that baseline KCC activity was higher in PKG transfected cells (PKG+) in comparison to PKG deficient 
cells (PKG-) [55]. Furthermore, the deletion of the KCC3 isoform has been shown to cause 
hypertension in mice [60,69]. These findings suggest that KCC may be involved in vasodilation 
through the NO/cGMP/PKG-PP1 pathway (Figure 2). 
A common modulator of both the PI3K/AKT and the NO/cGMP/PKG signaling cascades in the 
VSMCs is Apelin [70]. Apelin stimulates the NO pathway to induce vasodilation and the PI3K/Akt 
pathway to induce proliferation and migration of VSMCs [71]. Due to its cardioprotective effects in 
the VSMC’s, Apelin has been suggested as a novel therapeutic target in the cardiovascular system 
[71]. In 2013, researchers found that Apelin stimulated KCC activity through the NO pathway by 
336% and 142% by the MAPK/PI3K pathway [72]. In contrast, oxidized plasma cholesterol (oxLDL), 
a known promoter of vascular lesions, inhibited KCC by 70% and treatment with Apelin restored this 
function [72]. These studies prove that KCC3 has a physiological role in the vascular cells and thus 
has potential as a therapeutic target, however it is not clear if KCC acts through modifying the 
membrane potential, changes in cell volume, or influence of intracellular chloride activity. 
A study by Rust et al. reported an increase in [Cl−]i but no difference in vascular contractility in 
KCC3 knockout mice [69]. Instead, pharmacological inhibition of the sympathetic nervous system 
reduces blood pressure after 80 s and produced an increase in urinary excretion of catecholamine. 
Additionally, the isolated arteries from the KCC3 null mice did not respond differently to vasoactive 
interventions in comparison to wild type (WT) mice [69]. This suggests that KCC3 inactivation likely 
contributes to hypertension through neurogenic mechanisms and that the increase in [Cl−]i did not 
significantly affect vascular contractility. However, recent studies by Garneau et al. found normal 
levels of circulating catecholamine, supporting a role for KCC3 in the vasculature [73]. It is important 
to note that although both groups studied contractile properties, the study by Rust used isolated 
saphenous arteries while Garneau et al. used thoracic aortas. Furthermore, the isolated saphenous 
arteries used by Rust were hypertrophied and presented with increased [Cl−]i compared to the WT 
littermates. Thus more than one mechanism could be responsible for the cardiovascular phenotype. 
Taken together, these studies identified KCC as a key mediator of vascular pathologies. KCCs 
are implicated in atherosclerosis through their regulation by PDGF and in hypertension via 
regulatory NO (Figure 2). It is important to note that although the functional role of each KCC isoform 
remains obscure due to the lack of specific inhibitors for each KCC isoform, the comprehensive effects 
of KCC on VSMC proliferation is evident. 
5.2. KCC in Renal Cells 
Three isoforms, KCC1, KCC3 and KCC4 were found to be expressed in the kidney [74,75]. 
Although KCC1 is ubiquitous, its expression has only been studied at the mRNA level [22], thus the 
role of KCC1 in the kidney remains unknown. KCC3 is exclusively expressed in the basolateral 
membrane in the proximal tubule [76] and KCC4 is expressed in the basolateral membrane of 
proximal tubules [77], TAL and in alpha intercalated cells in the collecting duct. Although the first 
KCC isoform, KCC1, was identified in 1996 [22], in 1992, KCC was shown to be elevated in patients 
suffering from Liddle syndrome, an inherited form of high blood pressure [78], suggesting a tubular 
origin of the disease. However, the authors could not find further studies regarding the pathogenic 
role of KCC in Liddle syndrome. The primary defect in Liddle syndrome has since been identified to 
be mutations in the epithelial sodium channels (ENaC) subunits [79,80]. Melo et al. evaluated the 
expression level and distribution of KCC3 and KCC4 in rats exposed to hyperglycaemia, a low-salt 
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diet, metabolic acidosis and low or high K+ diet [56]. Consistent with the previous discovery of 
glucose stimulation of basolateral efflux of K+ ions [81], Melo et al. found that KCC3 mRNA and 
protein expression were increased during hyperglycaemia but not with low-salt diet or acidosis. In 
contrast, KCC4 protein expression was increased 1.53 ± 0.16-fold by a low sodium diet in the kidney 
and metabolic acidosis specifically in the alpha-intercalated cells of the collecting duct (CD) [56]. 
Overall, the results suggest that KCC3 is only involved in the glucose reabsorption mechanism as 
there is no overt renal phenotype detected in the KCC3 knockout mice models. Although the mice 
display arterial hypertension, the exclusive expression of KCC3 in the proximal tubule disavow their 
contribution to the hypertensive defects observed. Moreover, a causal relation between 
hypoglycemia to cardiovascular events has been much debated, thus, further research is needed. 
Contrastingly, the upregulated KCC4 expression in low-salt diet and metabolic acidosis implicates 
KCC4 in salt reabsorption of the TAL and acid secretion in the CD. More specifically, the increase in 
KCC4 activity during salt restriction could be a compensatory mechanism to promote basolateral K+ 
efflux to support salt transport. The findings from Melo are consistent with previous studies by 
Boettger et al. who reported renal tubular acidosis in KCC4 deficient mice [27]. Boettger reported 
compensated metabolic acidosis along with increased urine alkalinity in KCC4 knockout mice (pH 
7.3 ± 0.1) in comparison to the WT littermates (pH 6.4 ± 0.1) [27]. Energy-dispersive X-ray 
microanalysis revealed increased [Cl−]i in alpha-intercalated cells of KCC4 knockout mice. The alpha-
intercalated cells in the kidney secrete acid via the apical H-ATPase and H+/K+ exchanger and 
reabsorb bicarbonate via the basolateral Cl−/HCO3− exchanger (Figure 1) [57]. The rise in [Cl−]i 
indicates a more alkaline intracellular pH and electrochemical imbalance which inhibits apical H+ 
secretion, resulting in type 1 renal tubular acidosis. Cl− extrusion through KCC4 is important to 
negate the influx through the Cl−/HCO3− exchanger. Cl− import and bicarbonate extrusion through 
the Cl−/HCO3− compensate for the acid secretion on the apical side. Thus, KCC4 plays a physiological 
role in renal acidification. Loss of KCC4 leads to renal tubular acidosis, which presents with 
hypokalemia [57]. If hypokalemia is left untreated, cardiac arrhythmias can occur. In addition, renal 
tubular acidosis contributes to overall metabolic acidosis, an imbalance in the acid-base homeostasis. 
Metabolic acidosis commonly occurs in patients with chronic kidney disease (CKD). Although the 
relations between metabolic acidosis and CVD are obscure and thus require further studies, CVD is 
the leading cause of mortality in patients with CKD. 
6. Role of NKCC in Cardiovascular Disease 
Loop diuretics such as furosemide and bumetanide are antihypertensive, inhibiting sodium 
reabsorption in the kidney and consequently reducing blood pressure [53]. Loop diuretics are the 
mainstay treatment to promote diuresis in patients with congestive heart failure. Loop diuretics bind 
to the TM of NKCCs, a region that is highly conserved, and thus are not specific to one subfamily or 
their isoforms [29]. As such, pharmacological studies have revealed key roles for the ubiquitous 
NKCC1 and renal specific NKCC2 in vascular and renal cells respectively. NKCC1 is involved in the 
suppression of myogenic response in microcirculatory beds [51,82] and NKCC2 is involved in blood 
pressure regulation through sodium reabsorption. 
6.1. NKCC in Vascular Cells 
Studies by Garg et al. found that bumetanide is less efficient in hypertension due to a fixed aortic 
coarctation, a model for a fixed increase in resistance in the aorta, in comparison to hypertension by 
continuous infusion of norepinephrine [83]. One limitation of the study is that BP was measured 
under anesthesia. Despite the limitation of BP measurement under anesthesia, and the ambiguity 
around blood pressure regulation of NKCC1 or vice versa, it can be concluded that the hypotensive 
action of bumetanide is through systemic vascular resistance rather than cardiac output and that 
NKCC1 influences blood pressure through the smooth muscle tone in resistance vessels [84]. Like all 
muscle cells, VSMC responds to the rise in intracellular [Ca2+] concentration ([Ca2+]i) as a trigger for 
contraction. Thus myogenic tone is dependent on the influx of calcium [Ca2+] into VSMCs via voltage-
dependent Ca2+ channels and intracellular stores. Cl− channel activation leads to Cl− efflux, which 
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depolarizes the membrane. This activates the voltage-dependent Ca2+ channel and elevates [Ca2+]i. 
The rise in [Ca2+]i mediates myosin-actin interaction, cross-bridge cycling and consequently, VSMC 
contraction [85]. In the VSMC, NKCC1 is responsible for the inward-directed flux of Cl−. Consistent 
with the observation of reduced blood pressure in NKCC1 null mice, inhibition of NKCC1 by 
bumetanide decreased [Cl−], reduced Ca2+ uptake and completely blocked contraction [86]. This 
observation coupled with reports of lack of effect by bumetanide on contraction in response to KCl, 
which depolarizes smooth muscle cells directly, suggests that NKCC1 contributes to vascular tone 
via maintenance of [Cl−]i. Further studies have provred that this is accomplished through the channel 
opening of NKCC1 which increases the [Cl−]i above the electrochemical equilibrium which 
depolarizes the VSMC through activation of voltage-gated Ca2+ [87]. Consistent with previous 
findings, more recent studies in intact isolated thoracic aortas demonstrated that NKCC1 is involved 
in phenylephrine-induced rhythmic contraction in the mouse aorta and that NKCC1 is regulated by 
calcium sparks [88]. 
The myogenic tone is the ability of blood vessels to constrict. Constriction of vessels, elevates 
peripheral resistance, consequently raising blood pressure. Pharmacological inhibition with 
bumetanide, a potent inhibitor of both isoforms of NKCC, was found to suppress and block myogenic 
tone in mouse mesenteric arteries and rat afferent arterioles respectively [89,90]. However, the 
inhibitory action of bumetanide on myogenic tone and contractions are absent in NKCC1 null mice. 
This indicates that high ceiling diuretics (HCDs) influence myogenic tone via NKCC1 and that 
NKCC1 inhibition could lower blood pressure through effects on vascular cells. This is further 
supported by Meyer et al. who reported that tail-cuff measurements of blood pressure in NKCC1 
deficient mice were significantly lower than the WT mice [84,91]. Although previous studies using 
the same measurement method found no statically significant reduction in blood pressure in NKCC1 
null mice [92], the larger number of mice used by Meyer et al. and the longer length of the time period 
(21 days) suggests a role for NKCC1 in the maintenance of vascular tone. However, the BP 
measurements for the WT mice are quite high. This could be due to the tail-cuff method employed 
by the group as the method is operator dependent thus may produce less reliable results. Studies 
using radio telemetry, a method widely recognized as the best for establishing blood pressure 
phenotype, did not find a difference in NKCC1 KO mice vs. WT mice but found a difference when 
dietary salt was changed [84,93]. Despite the promising in vitro data from isolated vessels, studies of 
the whole animal are limited due to compensatory changes by the kidney. It is important to consider 
that although mice lacking NKCC1 have reduced blood pressure, the contractile effect of NKCC1 
does not necessarily translate into the effects of blood pressure in vivo. 
While NKCC1 is implicated in the maintenance of vascular tone, it may itself be regulated by 
blood pressure. A study by O’Donnell et al. showed that NKCC1 activity of the VSMC from 
spontaneously hypertensive rats is significantly less in comparison to normotensive rats [94]. 
Evidence also showed that NKCC1 activity is upregulated in different models of hypertension and is 
accompanied by an increase in [Cl−]i [95]. These models include hypertension elicited by 
deoxycorticosterone (DOCA)/salt and angiotensin 2 they showed that these caused increased levels 
of NKCC1 mRNA. Furthermore, aldosterone increases NKCC1 activity. Although it is clear that 
NKCC1 is implicated in the maintenance of vascular tone, NKCC1 upregulation in hypertensive 
models raises the question of whether NKCC1 activity and upregulation increase blood pressure or 
are the result of hypertension. Using rat aorta, Jiang et al. showed that after aortic coarctation, a 
procedure that yields both hypertensive and hypotensive segments of the aorta in the same animal, 
the NKCC1 activity of the hypertensive segment of the aorta is 62% greater than the control. There 
was also a 21% decrease in NKCC1 activity in the hypotensive segment of the aorta [96]. This is 
accompanied by observations of a fivefold increase in NKCC1 mRNA in the hypertensive aorta 
compared with the hypotensive or normotensive aorta. This supports the theory that blood pressure 
regulates NKCC1 in VSMCs. 
There is also evidence that epigenetic regulations of NKCC1 may play a role in its effects on the 
vascular tone [97]. A study by Lee et al. found that the expression of NKCC1 mRNA and protein 
levels in the aorta and heart tissues are higher in spontaneous hypertensive rats (SHR) than in 
Cells 2020, 9, 2293 11 of 22 
normotensive rats [51]. Lee also found greater hypomethylation of the NKCC1 gene promoter in the 
aorta and heart of the SHR relative to the normotensive rats. This was accompanied by increased 
NKCC1 expression and inhibitory action of bumetanide on mesenteric artery contractions with age 
in SHR but not wild type. The Emax for the dose–response curve was 74 ± 2.3 for SHR and 102 ± 4.7 
for normotensive rats. This suggests that promoter hypomethylation upregulates NKCC1 in SHR. 
Lee concluded that the upregulation of NKCC1 could be responsible for the development of high 
blood pressure in SHR. NKCC1 promoter hypomethylation could therefore be a marker of 
hypertension development. Further research by the same group found that the expression of NKCC1 
is epigenetically regulated during postnatal development of hypertension [98]. Sequencing revealed 
that the NKCC1 promoter in wild type rats was increasingly methylated with age (8.5%) but 
remained largely hypomethylated in SHR (2.2%) during postnatal development of hypertension. The 
activity of DNA methyl transferase 3B (DNMT3B), a family of enzymes that transfer a methyl group 
to promoter regions to downregulate their expression, is also three-fold higher in the aorta of wild 
type rats in comparison to SHR at 18 weeks of age. This suggests that the maintenance of 
hypomethylation of the NKCC1 promoter as a result of decreased DNMTB3B activity is the reason 
for the age-dependent development of hypertension in SHR. In a further study, Lee et al. noted that 
inhibition of DNMT with an inhibitor in the rat cerebral cortex resulted in the upregulation of the 
transcription of NKCC1 during postnatal maturation [46]. Another research group reported that 
DNMT inhibition also resulted in an increase in blood pressure [99]. Contrary to previous findings, 
these results could infer that age and blood pressure alter the NKCC1 promoter epigenetically. To 
elucidate the relationship between blood pressure and NKCC1 methylation, further study on 
vascular cells is required. 
NKCC1 can additionally be upregulated via histone modification in the aortas of angiotensin II 
(ang-II) induced hypertensive rats. Cho et al. found that the level of NKCC1 mRNA and protein in 
the aortas increased gradually in ang-II infused rats [100]. A histone activating code, acetylated 
histone H3, was increased and histone repressive code, trimethylated histone H3, was reduced in 
ang-II infused rats compared to the sham infused animals. Studies have shown that the recruitment 
of specificity protein 1 by CpG hypomethylation leads to the upregulation of NKCC1 in hypertensive 
rats [82]. This could mean that NKCC1 is epigenetically upregulated by histone modification or DNA 
demethylation upon the development of hypertension. The methylation of CpG dinucleotides may 
play a role in the epigenetic maintenance of blood pressure through decreased expression of NKCC1. 
These findings further emphasize NKCC1 methylation or histone modification as a potential 
biomarker in the diagnosis and management of hypertension. More recently, studies by Ji [101] and 
Andersen [102] et al. found increased NKCC1 activity after cardioplegia induced arrest of diabetic 
hearts and in post-infarction heart failure, respectively. These findings indicate the potential 
detrimental role of enhanced NKCC1 in the diabetic heart after cardioplegia infusions and in the 
promotion of adverse remodeling after myocardial infarction. 
These studies collectively suggest that inhibition of NKCC1, specifically in the smooth muscle 
could be a pharmacological target for hypertension. However, the ubiquitous nature of NKCC1 
coupled with the possibility of concurrent inhibition of NKCC2 in TAL, would preclude currently 
available NKCC1 inhibitors to be used in the treatment of cardiovascular disease. This is due to the 
large doses required to achieve an inhibitory response in the plasma which would produce 
unacceptable toxicity elsewhere [103]. Thus, a compound that selectively inhibits NKCC1 over 
NKCC2 and is not excreted via the urine is desirable. Indeed, Savardi et al. have now discovered a 
new drug candidate, termed ARN23746, which selectively inhibits NKCC1 versus NKCC2 in vivo 
[16]. 
6.2. NKCC in Renal Cells 
Despite the kidney-specific expression of NKCC2, NKCC1 has been found in several locations 
in the kidney including the inner medullary collecting duct. The basolateral expression of NKCC1 
results in salt and water secretion whereas the apical expression of NKCC2 in the thick ascending 
limb of the Loop of Henle results in salt reabsorption (Figure 1). Although mice that lack NKCC1 
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expression show impaired epithelial chloride secretion in the gut and trachea, later studies have not 
produced evidence to support a significant role of NKCC1 in chloride secretion in the kidney [104]. 
Loss-of-function mutations of NKCC2 results in the salt-wasting phenotype of type 1 Bartter 
Syndrome [105]. The secretory NKCC1 is also upregulated in metabolic acidosis [106]. An extensive 
account of the role of NKCC1 and NKCC2 in hypertension can be found in a recent review by Orlov 
et al. [107]. 
7. Hypothalamic Signaling Mechanisms in Hypertension 
The hypothalamus is crucial for the central control of blood pressure in response to central and 
peripheral stimuli. As such, there have been many studies implicating hypothalamic signaling 
mechanisms in hypertension. For the purpose of this review, we will only focus on the signals that 
directly involve CCCs. Those are the hypothalamic neuronal signaling mechanisms and the 
hypothalamic regulation of vasopressin secretion. A complete review of hypothalamic signaling 
mechanisms in hypertension can be found in a review by Carmichael et al. [49]. 
Accumulating evidence implicates increased sympathetic drive from the paraventricular 
nucleus (PVN) in the development of hypertension. More specifically, the hyperactivity of the PVN 
contributes to the elevated sympathetic drive. The excitability of the PVN is regulated by excitatory 
glutamatergic and inhibitory GABAergic inputs. Although GABA is the main inhibitory 
neurotransmitter in the brain, there is evidence that GABA can also elicit an excitatory response. The 
polarity of the neurotransmitter depends on the GABA equilibrium potential (EGABA). A more positive 
EGABA results in excitatory signaling and a more negative EGABA results in inhibitory signaling. The 
EGABA is influenced by [Cl−]i. If the [Cl−]i is high, the EGABA will be more positive and the GABA 
signaling will result in neuronal depolarization. If [Cl−]i is low, EGABA will be more negative and the 
response is an inhibitory and result in hyperpolarization. The [Cl−]in neurons are determined by two 
cation-chloride cotransporters, NKCC1 and KCC2 [108]. Thus, disruption of Cl− homeostasis leads to 
an imbalance of inhibitory and excitatory signals in the PVN. 
In SHR, GABAergic inhibition in the PVN is impaired [109]. Studies by Ye et al. revealed that 
the EGABA undergoes a depolarizing shift in SHR [47]. The inhibition of NKCC1 normalizes the EGABA 
and restores GABA inhibition of PVN in SHRs [47]. The mRNA and protein levels of NKCC1 but not 
KCC2 are significantly increased in SHRs and the inhibition of NKCC1 significantly reduces the 
sympathetic vasomotor tone [47]. This study provides evidence that NKCC1 activity is important for 
chloride homeostasis in the PVN. A disruption of the homeostasis diminishes the inhibitory effects 
of GABA resulting in the increased sympathetic outflow observed in hypertension. The 
hyperactivation of the PVN is supported by studies in a genetic mouse model of hypertension [109–
111]. 
Arginine vasopressin (AVP) is secreted by magnocellular neurosecretory cells (MNC) in the 
PVN. AVP stimulates water reabsorption in the kidney and causes vasoconstriction to maintain 
plasma osmolality and blood pressure respectively. In the development of salt-sensitive hypertension 
(DOCA), AVP secretion is dysregulated resulting in impairment in renal ionic absorption [112]. 
Studies by Yi et al. found an increase in AVP expression in the AVP of SHR [113]. This change 
increases both with age and magnitude of hypertension and is due to reduced GABAergic input from 
baroreceptors in response to high salt intake. Further findings by Kim et al. found that the inhibitory 
to excitatory switch of GABA receptors in AVP neurons contributes to the increased release of AVP 
observed in hypertension [112]. The switch is driven by the upregulation of NKCC1 and 
downregulation of KCC2. Recently, findings suggest that the downregulation of KCC is mediated by 
brain-derived neurotrophic factor via the tyrosine kinase receptor B (TrkB) pathway [44]. The 
downregulation of KCC prevents the inhibitory GABAergic signaling evoked by the baroreceptor 
which leads to increased excitability of AVP secreting neurons [44]. Although these studies confirm 
the significance of chloride homeostasis in the control of blood pressure, the role of vasopressin in 
neuronal mechanisms in hypertension still needs to be further elucidated. 
Viewed collectively, these studies provide insight into the regulation of sympathetic activity and 
chloride homeostasis in normotensive and hypertensive phenotypes in vivo. Sympathetic activity is 
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increased in hypertensive phenotypes due to disruption in chloride homeostasis following the 
upregulation of NKCC1. AVP secretion is increased due to the downregulation of KCC2. This 
suggests that further investigation of these mechanisms may uncover multiple therapeutic targets to 
reduce sympathetic activity and AVP release in hypertension. 
8. Role of Regulatory WNK-SPAK/OSR1 Pathway in Cardiovascular Disease 
Mutations in WNK1 and WNK4 genes caused a Mendelian form of hypertension, Familial 
Hyperkalemic Hypertension (FHHt) also known as pseudohypoaldosteronism type 2 or Gordon’s 
syndrome [42]. Although WNK1 is expressed in the mammalian DCT, expression levels are low and 
the predominant isoform in the DCT is a kidney-specific short isoform of WNK1 (ks-WNK1). Disease-
causing mutations in the WNK1 genes are intronic deletions that lead to the ectopic expression of 
full-length WNK1 and ks-WNK1 [114]. Mouse models overexpressing WNK1 display enhanced 
phosphorylation of NCC [115]. Further research identified a missense mutation in WNK4 (D564A) as 
the cause of hypertension in FHHt via activation of the WNK-OSR1/SPAK-NCC cascade [42]. This is 
supported by the observation that SPAK deficiency rescues FHHt caused by WNK4 mutation [116]. 
Although WNK4 is generally accepted as an activator of NCC, studies have found that WNK4 
modulates NKCC2 in vivo [117]. Knockout mouse models of WNK4 have been observed to possess 
lower levels of phosphorylated NCC and NKCC2 [84]. Homozygous WNK1 knockout in mice is 
embryonic lethal, however, studies of WNK1 heterozygous mice revealed a significant decrease in 
blood pressure [118]. Conversely, a study by Susa et al. found that the blood pressure in WNK1 
heterozygous mice was not reduced even when fed a low salt diet. The team also did not find a 
significant decrease in the phosphorylation of OSR1, SPAK, NCC, NKCC1 and NKCC2 in the kidney 
[119]. In contrast, a significant decrease in the phosphorylation of NKCC1 in the aorta and decreased 
pressure-induced myogenic response in the mesenteric arteries was observed in WNK1 heterozygous 
knockout mice. This is further supported by studies completed by the Bergaya team [120] who did 
not find a decrease in basal systolic blood pressure despite the use of radiotelemetry. Consistent with 
Susa et al., Bergaya et al. also found a major loss of contractile myogenic response in WNK1 
heterozygous mice that are associated with decreased phosphorylation level of WNK1 substrate 
SPAK and its target NKCC1 in arteries. These studies confirm the contribution of NKCC1 to the 
regulation of blood pressure and suggest a role for WNK1 in the regulation of NKCC1. Further 
studies in WNK1 knockout mice revealed that WNK1 is required for angiogenesis and heart 
development [121]. SPAK knockout mice present with Gitelman syndrome (hypokalemic metabolic 
alkalosis, hypomagnesemia and hypocalcaemia) and impaired vasoconstriction [122]. Thus SPAK has 
been suggested as an important pharmacological target for the treatment of essential hypertension 
[123]. More recent studies have shown that the upstream regulator of WNK, KLHL3 and CUL3, are 
implicated in FHHt. In particular, mutations in CUL3 causes severe hypertension by affecting both 
renal and vascular function [124–126]. More specifically, mice with mutant CUL3 protein showed 
increased expression of RhoA, a molecule involved in the regulation of vascular tone [124]. Further 
information on the mechanisms of CUL3/KLHL3 pathogenesis in FHHt can be found in a review by 
Ferdaus et al. [127]. 
We employed studies of phosphoproteomics and functional kinomics and found that WNKs 
regulate SPAK/OSR1, facilitating the phosphorylation of KCCs. This consequently reduces KCC 
activity, and the dephosphorylation of NKCC1, increasing NKCC1 function [33,39]. Thus, the same 
kinase pathway produces inverse effects on the opposing co-transporters, providing a powerful 
push–pull regulatory control of [Cl−]i. Through the use of an in vivo SPAK mouse model, we then 
uncovered a role for SPAK/OSR1 as a bridge to facilitate the signaling cascade between WNKs and 
CCCs [128]. SPAK/OSR1 was previously shown to phosphorylate CCCs earlier by the Delpire and 
Forbush labs [129,130]. Furthermore, we have developed a novel SPAK binding inhibitor, termed ZT-
1a, which specifically blocks the WNK-SPAK/OSR1-CCC signaling pathway, subsequently reducing 
the NKCC1 and KCCs phosphorylation in cultured cells, and in vivo mouse and rat tissues [6]. 
Although further studies are needed, this is promising for the treatment of cardiovascular disease as 
ZT-1a is an effective SPAK modulator. 
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9. Conclusion 
Together, these reviews highlight the potential role of CCCs in cardiovascular disease. The gain 
of function mutations of WNKs, resulting in the enhanced activity of NCC in the kidney, is the cause 
of FHHt. An increase in KCC activity in vascular cells could lead to atherosclerosis and have potential 
vasodilation effects. Impairment of KCCs in renal cells contribute to renal acidosis, a disease which, 
if not treated, could lead to cardiac arrhythmias. NKCC1 is epigenetically upregulated in 
hypertension. Impairment of NKCC2 in renal cells can cause Bartter syndrome. CCCs are also 
involved in hypothalamic signaling in hypertension and the mutations in the regulatory 
CUL3/KLHL3-WNK-SPAK/OSR1 pathway contribute to the pathology of FHHt. The future 
development of interventional strategies should exploit these recent findings pertaining to the role 
of CCCs in vascular and renal cells as well as the pathophysiological mechanisms involved in 
cardiovascular disease. 
Box 1 Measuring KCC3 and NKCC1 Activity Ion-Transport Activity 
The cation chloride cotransporters (CCC) are electroneutral thus electrophysiology methods that 
use voltage changes and electrical current cannot be used to measure CCC activity. Instead, 
researchers exploit the characteristic difference of the intracellular concentration of the ions to 
measure their activity instead. The most commonly used method is unidirectional Rb+ flux analysis 
to measure cotransporter activity [131]. The method uses non-radioactive Rubidium (86Rb+) as a 
potassium congener and measures the flux of 86Rb+. In order to characterize the transporter itself, all 
other transporters are blocked. For example, when studying KCC3 activity in VSMCs, ouabain and 
bumetanide were used to block Na+/K+ pump and NKCC1 activities. This method was used to clone 
and characterize the function of NKCCs [132] and the function of KCC3 [133]. More importantly, the 
technique allows for the study of channel properties in a variety of conditions including homogenous 
cell preparations; erythrocytes, oocytes and different heterologous cell lines. However, it is difficult 
to employ the methodology in brain slices and neuronal culture. Alternatively, fluorescent assays to 
measure the movement of thallium ions through potassium channels can be used [84]. This method 
uses TI+ as a surrogate of K+ and a TI+ sensitive fluorescent dye (FlixORTM) to visualize TI+ uptake 
through channels in single cells. The Delpire group reported similar results of both 86Rb+ and FluxOR 
methods [134]. Other techniques include the ammonium pulse technique which uses cardiac strips 
to measure the acidification rate [135]. A comparative analysis of measuring cation-chloride-
cotransporter activity can be found in a review by Medina et al. [131]. 
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